We are live on ! Find out more
CLLS

Cellectis

65 hedge funds and large institutions have $133M invested in Cellectis in 2020 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 20 increasing their positions, 18 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

33,600% more call options, than puts

Call options by funds: $337K | Put options by funds: $1K

150% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 6

11% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 18

8% more funds holding

Funds holding: 6065 (+5)

2.84% more ownership

Funds ownership: 31.15%34% (+2.8%)

41% less capital invested

Capital invested by funds: $226M → $133M (-$93.1M)

Holders
65
Holders Change
+5
Holders Change %
+8.33%
% of All Funds
1.43%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
15
Increased
20
Reduced
18
Closed
6
Calls
$337K
Puts
$1K
Net Calls
+$336K
Net Calls Change
+$6K

CLLS Hedge Fund Activity: Q1 2020 in Review

65 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Cellectis (CLLS) for Q1 2020, worth a combined $133M — down 41% from $226M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new CLLS positions and 6 closed out — a net gain of 9 holders — while 20 added to existing stakes and 18 trimmed.

The largest buyer was Capital International Inc, opening a new position worth an estimated $14.7M. The largest seller was Fidelity Investments, cutting an estimated $11.5M.

  • 65 institutional investors held Cellectis (CLLS) as of Q1 2020, up from 60 in Q4 2019.
  • Funds reported $133M of Cellectis stock for Q1 2020, down 41% quarter-over-quarter.
  • 15 funds opened new Cellectis positions in Q1 2020 and 6 closed out, a net change of +9 holders.
  • The largest Cellectis buyer in Q1 2020 was Capital International Inc, an estimated $14.7M added.
  • The largest Cellectis seller in Q1 2020 was Fidelity Investments, an estimated $11.5M sold.

Based on aggregated 13F filings for Q1 2020.